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httpSuccessful management of infected
thoracoabdominal graft and aortobronchial ﬁstula
using a hybrid approach
Patricia Giglio, BA, and Virendra I. Patel, MD, MPH, Boston, Mass
We present the case of a 72-year-old patient who underwent successful management of a thoracoabdominal aortic graft
infection. The patient was diagnosed with infected distal anastomotic pseudoaneurysm and aortobronchial ﬁstula after
type I thoracoabdominal aortic aneurysm repair. The infection was caused by the enteric gram-negative bacterium Proteus
mirabilis. The high-risk patient was successfully treated with visceral debranching, infrarenal aortic reconstruction, and
stent graft coverage of the pseudoaneurysm. The success of this case suggests that endovascular treatment of thor-
acoabdominal aortic graft infections may be a viable option in some high-risk patients. (J Vasc Surg Cases 2015;1:239-41.)Treatment of aortic graft infections continues to be a
challenge for surgeons. Graft infections after thoracic aortic
surgery occur at a rate of 0.9% to 2.0%.1 Débridement of
infection and graft explantation followed by vascular recon-
struction remain the “gold standard.” This approach is not
a viable option in high-risk patients; therefore, endovascu-
lar management and muscle ﬂap or omental wrap have
been suggested as treatment options for mycotic aneurysms
and aortobronchial ﬁstulas (ABFs).
This article presents a case of an infected distal anasto-
motic pseudoaneurysm (PSA) and ABF from extent I thor-
acoabdominal aortic aneurysm (TAAA) successfully treated
with visceral debranching and stent graft coverage. The
patient consented to the publication of this case report.
CASE REPORT
A 72-year-old man presented to an outside hospital with he-
moptysis. He reported lower back pain (8/10) and night sweats.
He denied dyspnea, fevers, chills, and weight change. Past medical
history was signiﬁcant for hypertension, type B aortic dissection,
hyperlipidemia, congestive heart failure, obesity, diverticulitis,
automatic implantable cardioverter-deﬁbrillator, and former smok-
ing. Past surgical history was aortic valve replacement and type Ithe Division of Vascular and Endovascular Surgery, Massachusetts
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://dx.doi.org/10.1016/j.jvsc.2015.07.006TAAA repair (2008) for degeneration of chronic dissection. The
distal anastomosis from the repair was approximately 2 cm above
the celiac artery, and the surgical dissection extended to the supe-
rior mesenteric artery (SMA).
The patient reported a persistent cough for 1 month before
admission that progressed to hemoptysis. Computed tomography
angiography (CTA) showed circumferential soft tissue density
8.7  8.0 cm at the level of the diaphragm, with PSA at the distal
graft anastomosis site with left lower lobe involvement. These ﬁnd-
ings (Fig 1) raised concern for ABF and infection of his thoracoab-
dominal graft.
The patient was transferred for surgical evaluation. He was he-
modynamically stable and afebrile. Laboratory results showed
white blood cell count of 15, creatinine concentration of 1.02,
and erythrocyte sedimentation rate of 99. Blood and sputum cul-
tures grew Proteus mirabilis. Cefepime, vancomycin, and metroni-
dazole (Flagyl) were initiated. The patient’s diagnosis was infected
distal anastomotic PSA from type I TAAA repair.
The patient was taken to the operating room for a debranch-
ing procedure and stent graft coverage of the PSA. He was
explored through a midline incision. The abdominal aorta was
exposed in standard inframesocolic fashion. The renal arteries,
SMA, and hepatic artery were mobilized. The infrarenal aorta
was replaced with a tube graft because of chronic dissection
extending from the celiac artery to the common iliac arteries.
The renal arteries, SMA, and common hepatic arteries were
debranched with bypass grafts. All arteries were ligated at their
origins. Two Gore TAG devices (W. L. Gore & Associates, Flag-
staff, Ariz) were placed over the ruptured descending aorta, with
the proximal seal zone at the level of the proximal TAAA graft
and the distal seal within the new infrarenal graft. The visceral
grafts were wrapped with omentum, and the abdomen was
closed.
The patient remained on broad-spectrum antibiotics for a
week. He was converted to intravenous ceftriaxone and metroni-
dazole for 2 weeks, then prescribed 500 mg of ciproﬂoxacin indef-
initely. He was discharged on postoperative day 19. At a 4-month
follow-up, CTA revealed nearly complete resolution of his PSA.
Three years after the procedure, he is asymptomatic, and CTA
shows no signs of infection or inﬂammation (Fig 2). The patient239
Fig 1. Preoperative axial computed tomography angiography (CTA) images. A, Axial CTA image showing the
phlegmon (arrow) and lung involvement around the distal thoracoabdominal graft. B, Axial CTA image showing the
distal anastomotic pseudoaneurysm (PSA).
Fig 2. Computed tomography angiography (CTA) images at 3-year follow-up showing complete resolution of
inﬂammation and infection. A, Axial image at level of distal thoracoabdominal graft. B, Candy cane digital
reconstruction.
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DISCUSSION
Management of aortic graft infections varies. Classical
treatment is resection of the graft, débridement of the
infected aorta and surrounding tissue, and arterial recon-
struction followed by long-term antibiotic therapy.1-3
Treatment has shifted to in situ reconstruction with an
antibiotic-impregnated graft, omental wrap, and long-
term antibiotic suppression.4-6 This approach is not always
a viable option, and choosing the appropriate therapy for
high-risk patients is difﬁcult.7 For successful outcomes, sur-
geons treating aortic graft infections should be familiar
with multiple treatment options, be experienced in compli-
cated reconstructions, and provide long-term follow-up.8
There are alternative approaches for treatment of aortic
graft infections. Cases report successful treatment of pa-
tients with muscle ﬂap coverage or omental wrappingwithout graft resection.1,2 The high vascularity and absorp-
tivity of the omental tissue enhances immune reaction and
decreases ﬂuid collection, which decreases reinfection
rates.9 Another less invasive option for patients is removal
of grossly infected tissue, washout, and placement of
antibiotic-impregnated beads around the graft.10
Whereas thoracic endovascular aortic repair (TEVAR)
has evolved as an important therapy for thoracic aortic dis-
eases, treatment of graft infections with TEVAR contra-
dicts general surgical principles. This approach results in
placement of foreign material in an infected ﬁeld, and mea-
sures to reduce infection (ie, débridement) are not used.
Consequently, several studies suggest that endovascular
procedures may be used to bridge resection and aortic
reconstruction in high-risk patients.3,6,11
The use of TEVAR in treating ABFs is also debated.
The literature reports 91% to 100% intraoperative technical
success and 30-day mortality rates ranging from 1.5% to
40% for TEVAR of ABFs.11-15 Studies reporting 100%
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and hemoptysis, and no TEVAR failure suggest that
TEVAR is a deﬁnitive treatment of ABF.12,14 In contrast,
retrospective reviews found high risk of infectious compli-
cations, recurrent bleeding, and recurrent ABF.11,15 These
reviews suggest that TEVAR initially controls hemody-
namics, but risk factors must be assessed to determine if a
second procedure is necessary. In this case of a mycotic
PSA and ABF, risk factors were considered, and treatment
of ABF with TEVAR was intended as a bridge procedure.
Our patient presented with a thoracoabdominal graft
infection and ABF. A two-stage surgical approach was
selected because of the patient’s clinical and physical dete-
rioration before presentation. The stage one procedure
consisted of visceral debranching, infrarenal aortic recon-
struction, and stent graft coverage of the PSA. This proce-
dure minimized technical risk and risk of prolonged visceral
ischemia because vessels were dissected at locations
removed from the infection, phlegmon, and prior surgical
bed. The planned second-stage procedure consisted of
excision of the newly placed TEVAR, affected aorta, and
distal aspect of the old infected graft with in situ recon-
struction using an antibiotic-impregnated graft. However,
the patient did not appear clinically or physically ready
for a major surgical resection at 4-month follow-up. Serial
computed tomography follow-up continued to show
improvement. CTA now shows complete resolution of
infection. The patient is fully functional, is asymptomatic,
and has normal erythrocyte sedimentation rate and white
blood cell count. The bridge operation successfully treated
the patient’s ABF and PSA, and the second stage was
unnecessary.
CONCLUSIONS
This article reports a successful hybrid repair of an
infected distal anastomosis PSA and ABF caused by
P. mirabilis. Complete resection of affected material with
in situ reconstruction is the preferred treatment for aortic
graft infection. However, the success of this case suggests
that a hybrid endovascular and open approach may be a
viable treatment option in similar high-risk patients with
graft infections, ABF, or PSA. TEVAR is preferred in emer-
gent ABF cases. Risk factors dictate whether TEVAR is a
deﬁnitive treatment or a bridge procedure. Patients pre-
senting with infection must be monitored after TEVAR
because of risk of recurrent infection, ABF, and hemopty-
sis. Positron emission tomography/computed tomography
imaging before or after intervention is suggested as it is re-
ported to be more accurate in diagnosis of patients with
suspected graft infection.16-18 Flushing of the stent graft
with rifampicin might also be considered to minimize rein-
fection.6,12 After TEVAR, patients should be prescribed
long-term suppressive antibiotic indeﬁnitely. Bronchoscopy
may be used to monitor infection in patients with persistent
symptoms. However, patients with recurrent infection
should be treated with a second-stage open procedure.REFERENCES
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